Dermorphin Reconstitution Calculator

No. Dermorphin is not FDA-approved or registered as a pharmaceutical. A 1985 randomized, placebo-controlled trial of intrathecal dermorphin for postoperative pain reported superiority to morphine, but clinical development was not pursued. Human experimental data exist for spinal nociceptive reflex inhibition, but dermorphin remains a research and doping-controlled substance.

Dermorphin is used parenterally. Historically, human administration was intrathecal. In animal studies, subcutaneous, intraperitoneal, intranasal, and intracerebroventricular routes produced analgesia (animal). Oral bioavailability is poor; an intranasal dermorphin analogue produced analgesia at 0.5–1.0 µg/kg in rats, and an intraperitoneal dose of 5.0 mg/kg produced >50% analgesia. The peripherally restricted analogue DALDA reduced pain behavior at 1–10 mg/kg subcutaneous in rats. Oral use has been explored only with modified cyclic dermorphin analogues in mice.

No. Kambo is a frog skin secretion from Phyllomedusa bicolor containing dermorphins, deltorphins, phyllocaerulein, phyllomedusin, sauvagine, and other bioactive peptides. It is not a purified dermorphin product. Kambo use has caused severe hyponatremia, cerebral edema, and brain death after ritual application, and an electrodiagnostically confirmed acute demyelinating polyneuropathy. It should not be used as a delivery route for dermorphin.

Dermorphin is a potent µ-opioid receptor agonist. In rats, intravenous bolus dermorphin caused immediate apnea via µ1 opioid receptors, and a dermorphin-ranatensin hybrid induced apnea in 70% of anesthetized rats (animal). In humans, Kambo-associated dermorphin exposure has produced life-threatening hyponatremia, cerebral edema, and death (case reports). Pregnancy/lactation human safety data are absent; opioid peptides pose theoretical risk of respiratory depression and dependence.

Preclinical and historical human data indicate dermorphin is more potent than morphine. The 1985 intrathecal trial reported superior postoperative analgesia with dermorphin versus morphine. In rats, dermorphin showed faster respiratory recovery than fentanyl after intravenous bolus, but still produced apnea. Unlike conventional opioids, dermorphin contains a D-amino acid at position 2, conferring high µ-receptor affinity and reduced proteolytic degradation (mechanistic).

No pharmaceutical half-life is established in humans. In human liver microsomes and zebrafish, the major metabolite was the N-terminal tetrapeptide YAFG-OH (m/z 457.2085), proposed as the primary detection target. Doping-control methods for human urine detect dermorphin and dermorphin(1–4) with a limit of detection/identification of 2.5 ng/mL.

Yes. Dermorphin is a banned substance in equine sport and is detectable in human and equine urine/plasma by LC-HRMS and LC-MS/MS methods. Athletes should assume dermorphin is prohibited in human sport under WADA-class peptide hormone rules. There are no legitimate medical-use exemptions for research peptides.

No published stability data for dermorphin are available in the corpus. Standard peptide handling of lyophilized product at −20°C or refrigerated after reconstitution is prudent (community protocol).